Bayer Launches Japan Open Innovation Hub From Kobe Base
Bayer Pharmaceuticals launched Co.Lab Japan, an open innovation platform linking Japanese startups and academia to global pharma networks, with inaugural event in Kobe featuring three engagement programs.
KOBE — Bayer Pharmaceuticals launched Bayer Co.Lab Japan on October 1, an open innovation platform connecting Japanese life sciences startups and academic labs to global pharma networks, with a kickoff event at Kobe Biomedical Innovation Cluster.
The program offers three engagement formats: Office Hours for one-on-one consultations, Dialogue Modules for focused topic discussions, and Deep Dive Day sessions bringing together corporates, venture investors, and researchers. Friedemann Janus, global head of Bayer Co.Lab, said Japan produces world-class science but gaps remain in commercialization; the platform brings Bayer expertise and global networks into early-stage research dialogue.
The Kobe event featured case discussions on low-dose gene therapy for heart failure and microRNA cancer drugs. Participants emphasized defining competitive advantage early, mapping regulatory and manufacturing pathways from the outset, and bringing commercialization specialists into research phases. Kobe-based RegCell, developing regulatory T-cell therapies for autoimmune diseases, presented its platform; the startup plans U.S. clinical trials in 2026. Chief scientist Shimon Sakaguchi received the 2025 Nobel Prize in Physiology or Medicine for work underlying RegCell’s approach.
Bayer’s platform addresses a known barrier for Japanese biotech: accessing pharma validation and global networks early enough to shape development strategy. Kobe anchors the nationwide rollout.